Evidence map›Paper›PMID 34080081›Full record

SynthesisClinical rheumatology2021

Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.

Xinyu Ma, Rui Tang, Mei Luo, Zhuotong Zeng, Yaqian Shi, Bingsi Tang, Rong Xiao

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Systemic Sclerosis Association with Malignancy.Clinical reviews in allergy & immunology · 2022
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Xinyu MaDepartment of Dermatology, The Second Xiangya Hospital, Central South University, #139 Road Renmin, Changsha, 410011, Hunan, China.
Rui TangDepartment of Rheumatology and Immunology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Mei LuoDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhuotong ZengDepartment of Dermatology, The Second Xiangya Hospital, Central South University, #139 Road Renmin, Changsha, 410011, Hunan, China.
Yaqian ShiDepartment of Dermatology, The Second Xiangya Hospital, Central South University, #139 Road Renmin, Changsha, 410011, Hunan, China.
Bingsi TangDepartment of Dermatology, The Second Xiangya Hospital, Central South University, #139 Road Renmin, Changsha, 410011, Hunan, China.
Rong XiaoDepartment of Dermatology, The Second Xiangya Hospital, Central South University, #139 Road Renmin, Changsha, 410011, Hunan, China. xiaorong65@csu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study systematically compares the efficacy and adverse events of mycophenolate mofetil (MMF) and cyclophosphamide (CYC) in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).

methodsThe EMBASE and PubMed databases were systematically searched to find all relevant studies. Quality assessment, study selection, and data extraction were independently conducted by two reviewers. The mean changes in forced vital capacity (FVC)% and diffusing capacity for carbon monoxide (DLco)% of the patients were selected to be primary outcome measures. Stata software was used for the pooled analysis.

resultsAmong 284 titles screened from multiple databases, six studies met the inclusion criteria (one randomized controlled trial, three prospective observational studies, and two retrospective observational studies). The summary weighted mean difference (WMD) of FVC change in the MMF group compared with the CYC group was - 1.17 (95% CI: - 2.713, 0.373; P = 0.137), and the summary WMD of DLco change in the MMF group compared with the CYC group was 2.245 (95% CI: 0.258, 4.232; P = 0.027). Studies enrolled showed that adverse events were less common in the MMF group.

conclusionsThe efficacy of MMF with respect to FVC and DLco improvement is comparable to that of CYC, and MMF is preferred on the basis of the occurrence of adverse events. Key Points • A systematic review and meta-analysis was conducted to compare the efficacy and adverse events of mycophenolate mofetil and cyclophosphamide in patients with systemic sclerosis-related interstitial lung disease. • The efficacy of MMF with respect to FVC and DLco improvement is comparable to that of CYC, and MMF is preferred on the basis of the occurrence of adverse events.

Indexed as

Lung Diseases, InterstitialScleroderma, SystemicCyclophosphamideHumansImmunosuppressive AgentsMycophenolic AcidObservational Studies as TopicRetrospective StudiesTreatment OutcomeCyclophosphamideImmunosuppressive AgentsMycophenolic AcidCyclophosphamideInterstitial lung diseaseMeta-analysisMycophenolate mofetilSystemic sclerosis

Identifiers

PMID34080081

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.